LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Home・Akcijų sąrašas・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Uždarymo kaina

1.5 -0.66

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.48

Max

1.52

Pagrindiniai rodikliai
By Trading Economics
P/E Sektoriaus vid.	8 56.602
Darbuotojai	8

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+224.68% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-2.8M 10M
Ankstesnė atidarymo kaina	2.16
Ankstesnė uždarymo kaina	1.5

Minerva Neurosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-15 22:52; UTC

Uždarbis

Pagrindinės rinkos jėgos

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

2025-05-15 20:37; UTC

Svarbiausios naujienos

Uždarbis

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

2025-05-16 00:00; UTC

Rinkos pokalbiai

Xero Bull Stays Positive on Cost Outlook -- Market Talk

2025-05-15 23:47; UTC

Rinkos pokalbiai

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

2025-05-15 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-15 23:38; UTC

Rinkos pokalbiai

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025-05-15 23:14; UTC

Svarbiausios naujienos

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

2025-05-15 22:46; UTC

Svarbiausios naujienos

Įsigijimai, susijungimai, perėmimai

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025-05-15 21:58; UTC

Uždarbis

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

2025-05-15 21:24; UTC

Uždarbis

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

2025-05-15 20:56; UTC

Rinkos pokalbiai

U.S. Spending Downturn Could Lie Ahead -- Market Talk

2025-05-15 20:54; UTC

Rinkos pokalbiai

Uždarbis

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

2025-05-15 20:54; UTC

Uždarbis

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

2025-05-15 20:51; UTC

Uždarbis

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

2025-05-15 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-05-15 20:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

2025-05-15 20:50; UTC

Uždarbis

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

2025-05-15 20:26; UTC

Svarbiausios naujienos

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

2025-05-15 20:25; UTC

Uždarbis

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Minerva Neurosciences Inc Prognozė

Kainos tikslas

By TipRanks

224.68% į viršų

12 mėnesių prognozė

Vidutinis 5 USD 224.68%

Aukščiausias 5 USD

Žemiausias 5 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Minerva Neurosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Minerva Neurosciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Apie bendrovę Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.